RecruitingOBSERVATIONAL

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

This study is looking at how different treatment approaches affect people who develop Multiple Sclerosis (MS) after the age of 50. Researchers are comparing two main strategies: one where treatment starts strong, and another where treatment strength is increased over time if needed. The aim is to see which approach is better at preventing MS flare-ups and reducing side effects. They also want to identify factors that might lead to an MS relapse or problems with treatment. This isn't a new drug trial; instead, it's a review of existing patient information to understand how current treatments are working. The findings could help doctors decide the best way to manage MS for older patients.

At a glance

Status

Recruiting

Sponsor

University Hospital, Strasbourg, France

Enrolment target

830

Start

07 Feb 2025

Estimated completion

01 Feb 2026

Multiple Sclerosis (MS)

What is this study about?

This study is helping us understand the best way to treat Multiple Sclerosis (MS) in people who are diagnosed after their 50th birthday. MS is a condition that affects your brain and spinal cord, and symptoms can vary widely. When you’re diagnosed, doctors need to decide on the best treatment to help control the condition and prevent new flare-ups, also known as relapses.

In this study, researchers are looking back at the information of patients who have already been treated. They are comparing two main treatment approaches. In one approach, called the 'escalation group', people might start with a milder treatment, and if their MS isn't well controlled, their doctors might then increase the strength of their medication. In the other approach, called the 'induction group', people start with a stronger treatment from the outset.

The main goal is to see which of these ways of treating MS leads to fewer flare-ups and fewer problems with treatment for people who develop MS later in life. They also want to discover if there are any specific reasons why some people experience relapses or treatment complications more often. This research is important because it can help doctors make more informed decisions about the best starting treatment for older patients with MS, potentially leading to better outcomes and quality of life.

Key takeaways

The study looks at MS treatment strategies for people diagnosed after age 50.
It compares starting with stronger treatments versus gradually increasing treatment strength.
Researchers are reviewing existing patient records, not conducting new drug trials or requiring new patient participation.
The goal is to reduce MS flare-ups and treatment complications.
It aims to identify factors linked to relapses or treatment problems.
The findings could help doctors choose the best initial treatment for older MS patients.

Who may be eligible?

This study is looking at records of people who developed a type of MS called Relapsing-Remitting MS (RRMS) after they turned 50 years old. To be included, they also needed to have started their first MS treatment within two years of noticing their first symptoms.

The study includes people who were treated with either moderately effective MS medications (like teriflunomide or glatiramer acetate) or highly effective MS medications (like fingolimod or rituximab).

However, if someone had an early, rapidly worsening form of MS (called early progressive MS), their information would not be included in this study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Were you diagnosed with Relapsing-Remitting MS?
Did your MS symptoms start after your 50th birthday?
Did you begin your first MS treatment within two years of your first symptoms?
Have you been treated with common MS medications (either moderately or highly effective ones)?
Have you NOT been diagnosed with early progressive MS?

Answer every question to see your result.

What does participation involve?

This study is not asking new patients to participate in a trial or to take any new medications. Instead, researchers are looking at existing medical records and information of people who have already been treated for MS. This means you do not need to attend any extra visits, undergo new assessments, or take any study-specific medication. Your past treatment and health information, if it fits the study criteria, might be reviewed anonymously as part of this research. There is no direct involvement required from individual patients.

Potential risks and benefits

Since this study involves looking at existing, anonymised patient records, there are no direct physical risks to individuals. The benefit of taking part (indirectly, by having your de-identified past data included) is that your past treatment journey could contribute valuable insights into finding the best ways to treat MS for others in the future. You have the right to decline your medical records being used for research at any time, if this is something your clinic or doctor offers as an option for existing data.

Locations (1)

Centre d'Investigation Clinique - CHU de Strasbourg - France
Verified postcode
Strasbourg, France· Recruiting

Common questions

What kind of MS is this study about?

This study focuses on Relapsing-Remitting MS (RRMS) that develops after age 50.

Do I need to take new medication for this study?

No, this study looks at past treatments and medical records; no new medication is involved for participants.

What does 'escalation' vs 'induction' mean in MS treatment?

'Escalation' often means starting with a milder treatment and increasing its strength if needed. 'Induction' means starting with a stronger treatment from the beginning.

Will my personal details be used?

No, if your data is used, it will be anonymised, meaning your name and personal details will not be connected to the information.

Why is this research important for older MS patients?

It helps doctors understand which treatment strategies work best for MS when it starts later in life, potentially leading to more effective care.

How to find out more

Nicolas Collongues, MD

nicolas.collongues@chru-strasbourg.fr 33 3.88.12.87.33 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.